Adc Therapeutics Sa Stock Total Debt

ADCT Stock

USD 1.72 0.07 4.24%

ADC Therapeutics SA fundamentals help investors to digest information that contributes to ADC Therapeutics' financial success or failures. It also enables traders to predict the movement of ADC Stock. The fundamental analysis module provides a way to measure ADC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADC Therapeutics stock.

Other Current Liab Total Assets

Total Debt To Capitalization is likely to gain to -5.69 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ADC Therapeutics SA Company Total Debt Analysis

ADC Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current ADC Therapeutics Total Debt

124.38 M

Most of ADC Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADC Therapeutics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ADC Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for ADC Therapeutics is extremely important. It helps to project a fair market value of ADC Stock properly, considering its historical fundamentals such as Total Debt. Since ADC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADC Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Property Plant Equipment	Capital Stock	Short Term Debt	Long Term Debt	Long Term Investments	Short Long Term Debt	Deferred Long Term Liab
Total Assets		-0.11	0.52	-0.74	-0.79	0.73	0.68	0.78	1.0	0.83	0.83	-0.34	-0.24	0.0	0.86	0.8	0.83	0.7	0.04	-0.45	0.61	0.49
Total Stockholder Equity	-0.11		-0.77	-0.52	0.65	-0.62	-0.39	-0.7	-0.15	-0.5	-0.46	0.8	0.65	0.94	0.06	-0.54	-0.5	0.32	0.41	0.9	-0.76	-0.81
Current Deferred Revenue	0.52	-0.77		0.07	-0.73	0.78	0.69	0.85	0.54	0.63	0.53	-0.74	-0.61	-0.67	0.38	0.68	0.57	0.03	-0.28	-0.82	0.82	0.78
Net Debt	-0.74	-0.52	0.07		0.25	-0.23	-0.15	-0.21	-0.73	-0.35	-0.38	-0.29	-0.17	-0.57	-0.76	-0.29	-0.36	-0.86	-0.39	-0.15	0.03	0.15
Retained Earnings	-0.79	0.65	-0.73	0.25		-0.91	-0.7	-0.96	-0.8	-0.95	-0.94	0.76	0.51	0.58	-0.5	-0.93	-0.95	-0.3	0.23	0.86	-0.89	-0.84
Accounts Payable	0.73	-0.62	0.78	-0.23	-0.91		0.68	0.88	0.76	0.93	0.84	-0.74	-0.37	-0.59	0.43	0.89	0.84	0.24	-0.08	-0.8	0.91	0.85
Net Receivables	0.68	-0.39	0.69	-0.15	-0.7	0.68		0.71	0.67	0.71	0.68	-0.61	-0.17	-0.27	0.5	0.74	0.68	0.13	-0.25	-0.49	0.8	0.71
Total Liab	0.78	-0.7	0.85	-0.21	-0.96	0.88	0.71		0.8	0.88	0.86	-0.73	-0.64	-0.59	0.58	0.89	0.89	0.29	-0.28	-0.89	0.88	0.84
Total Current Assets	1.0	-0.15	0.54	-0.73	-0.8	0.76	0.67	0.8		0.84	0.84	-0.34	-0.26	-0.03	0.86	0.81	0.84	0.68	0.03	-0.49	0.63	0.52
Intangible Assets	0.83	-0.5	0.63	-0.35	-0.95	0.93	0.71	0.88	0.84		0.97	-0.72	-0.33	-0.47	0.49	0.97	0.96	0.39	-0.07	-0.72	0.86	0.78
Common Stock	0.83	-0.46	0.53	-0.38	-0.94	0.84	0.68	0.86	0.84	0.97		-0.62	-0.32	-0.38	0.56	0.96	0.99	0.42	-0.09	-0.69	0.82	0.75
Net Tangible Assets	-0.34	0.8	-0.74	-0.29	0.76	-0.74	-0.61	-0.73	-0.34	-0.72	-0.62		0.5	0.86	0.07	-0.74	-0.65	0.13	0.33	0.75	-0.76	-0.75
Capital Surpluse	-0.24	0.65	-0.61	-0.17	0.51	-0.37	-0.17	-0.64	-0.26	-0.33	-0.32	0.5		0.62	-0.17	-0.32	-0.41	0.11	0.7	0.72	-0.43	-0.54
Net Invested Capital	0.0	0.94	-0.67	-0.57	0.58	-0.59	-0.27	-0.59	-0.03	-0.47	-0.38	0.86	0.62		0.29	-0.47	-0.42	0.43	0.43	0.83	-0.67	-0.73
Net Working Capital	0.86	0.06	0.38	-0.76	-0.5	0.43	0.5	0.58	0.86	0.49	0.56	0.07	-0.17	0.29		0.51	0.56	0.73	0.13	-0.26	0.37	0.27
Property Plant Equipment	0.8	-0.54	0.68	-0.29	-0.93	0.89	0.74	0.89	0.81	0.97	0.96	-0.74	-0.32	-0.47	0.51		0.95	0.42	0.0	-0.71	0.85	0.75
Capital Stock	0.83	-0.5	0.57	-0.36	-0.95	0.84	0.68	0.89	0.84	0.96	0.99	-0.65	-0.41	-0.42	0.56	0.95		0.41	-0.16	-0.73	0.82	0.76
Short Term Debt	0.7	0.32	0.03	-0.86	-0.3	0.24	0.13	0.29	0.68	0.39	0.42	0.13	0.11	0.43	0.73	0.42	0.41		0.59	0.08	-0.01	-0.17
Long Term Debt	0.04	0.41	-0.28	-0.39	0.23	-0.08	-0.25	-0.28	0.03	-0.07	-0.09	0.33	0.7	0.43	0.13	0.0	-0.16	0.59		0.43	-0.3	-0.48
Long Term Investments	-0.45	0.9	-0.82	-0.15	0.86	-0.8	-0.49	-0.89	-0.49	-0.72	-0.69	0.75	0.72	0.83	-0.26	-0.71	-0.73	0.08	0.43		-0.87	-0.91
Short Long Term Debt	0.61	-0.76	0.82	0.03	-0.89	0.91	0.8	0.88	0.63	0.86	0.82	-0.76	-0.43	-0.67	0.37	0.85	0.82	-0.01	-0.3	-0.87		0.97
Deferred Long Term Liab	0.49	-0.81	0.78	0.15	-0.84	0.85	0.71	0.84	0.52	0.78	0.75	-0.75	-0.54	-0.73	0.27	0.75	0.76	-0.17	-0.48	-0.91	0.97

Click cells to compare fundamentals

ADC Total Debt Historical Pattern

Today, most investors in ADC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ADC Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ADC Therapeutics total debt as a starting point in their analysis.

ADC Therapeutics Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict ADC Therapeutics

Short Long Term Debt Total Over Time

ADC Net Debt

Net Debt

(145.74 Million)

At this time, ADC Therapeutics' Net Debt is comparatively stable compared to the past year.

Based on the latest financial disclosure, ADC Therapeutics SA has a Total Debt of 124.38 M. This is 95.48% lower than that of the Communications Equipment sector and 61.7% lower than that of the Information Technology industry. The total debt for all United States stocks is 97.66% higher than that of the company.

ADC Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.

ADC Therapeutics is currently under evaluation in total debt category among its peers.

ADC Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	2.1B	1.6B	300.1M	135.6M	156.0M	148.2M
Enterprise Value	1.7B	1.2B	91.0M	(18.6M)	(21.4M)	(20.3M)

ADC Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in ADC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ADC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ADC Therapeutics' value.

		Shares
Geode Capital Management, Llc	2024-09-30	953.2 K
Vantage Consulting Group Inc.	2024-09-30	850.7 K
Blue Owl Capital Holdings Lp	2024-09-30	733.6 K
Millennium Management Llc	2024-09-30	712.4 K
Vanguard Group Inc	2024-09-30	539.4 K
Northern Trust Corp	2024-09-30	481 K
Gcm Grosvenor Holdings, Llc	2024-09-30	410.9 K
D. E. Shaw & Co Lp	2024-09-30	284.2 K
Two Sigma Investments Llc	2024-09-30	245.3 K
Redmile Group, Llc	2024-09-30	15.7 M
Prosight Management, Lp	2024-09-30	9.6 M

ADC Fundamentals

	Return On Equity	-7.06
	Return On Asset	-0.21
	Profit Margin	(3.00) %
	Operating Margin	(1.93) %
	Current Valuation	16.59 M
	Shares Outstanding	96.69 M
	Shares Owned By Insiders	20.64 %
	Shares Owned By Institutions	61.61 %
	Number Of Shares Shorted	5.18 M
	Price To Earning	19.80 X
	Price To Book	2.58 X
	Price To Sales	2.35 X
	Revenue	69.56 M
	Gross Profit	(59.85 M)
	EBITDA	(146.76 M)
	Net Income	(240.05 M)
	Cash And Equivalents	376.78 M
	Cash Per Share	4.90 X
	Total Debt	124.38 M
	Debt To Equity	2.75 %
	Current Ratio	5.76 X
	Book Value Per Share	(1.78) X
	Cash Flow From Operations	(118.69 M)
	Short Ratio	5.96 X
	Earnings Per Share	(2.39) X
	Price To Earnings To Growth	0.74 X
	Target Price	8.4
	Number Of Employees	273
	Beta	1.6
	Market Capitalization	166.31 M
	Total Asset	354.78 M
	Retained Earnings	(1.34 B)
	Working Capital	268.62 M
	Current Asset	1.11 B
	Current Liabilities	288.7 M
	Net Asset	354.78 M

About ADC Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC